Method for the Selective Measurement of Amino-Terminal Variants of Procalcitonin
Open Access
- 1 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (9), 1672-1679
- https://doi.org/10.1373/clinchem.2008.123018
Abstract
Background: Procalcitonin (PCT) is an established marker for diagnosing and monitoring bacterial infections. Full-length PCT [116 amino acids that make up procalcitonin (PCT1–116)] can be truncated, leading to des-Ala-Pro-PCT (des-Alanin-Prolin-Procalcitonin; PCT3–116). Current immunoassays for PCT (“total PCT”) use antibodies directed against internal epitopes and are unable to distinguish amino-terminal PCT variants. Here we describe the development of monoclonal antibodies recognizing the amino-termini of PCT1–116 and PCT3–116 and their use in the selective measurement of these PCT species. Methods: With newly developed monoclonal antibodies against the amino-termini of PCT1–116 and PCT3–116, and an antibody against the katacalcin moiety of PCT, we developed and characterized immunoluminometric assays for the 2 PCT peptides. We comparatively assessed the kinetics of PCT variants in a human endotoxemia model. Results: Monoclonal antibodies against the amino-termini of PCT1–116 and PCT3–116 showed <1% cross-reactivity with other PCT-related peptides. The sandwich assays for PCT1–116 and PCT3–116 had functional assay sensitivities of 5 and 1.2 pmol/L, respectively, and exhibited recoveries within 20% of expected values. Plasma PCT1–116 was stable for 6 h at 22 °C and 24 h at 4 °C, and PCT3–116 was stable for at least 24 h at both temperatures. During experimental endotoxemia in healthy people, both PCT1–116 and PCT3–116 increased early in parallel with total PCT, but further increases in PCT1–116 were significantly slower than for PCT3–116 (P = 0.0049) and total PCT (P = 0.0024). Conclusions: The new assays selectively measure PCT1–116 and PCT3–116. Both PCT species increase early during endotoxemia but differ in their kinetics thereafter. The selective measurement of PCT species with different in vivo kinetics may be useful in improving PCT-guided therapies.Keywords
This publication has 22 references indexed in Scilit:
- Procalcitonin-Guided Antibiotic Use vs a Standard Approach for Acute Respiratory Tract Infections in Primary CareArchives of Internal Medicine, 2008
- Use of Procalcitonin to Shorten Antibiotic Treatment Duration in Septic PatientsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitationsCritical Care Medicine, 2008
- Antibiotic Treatment of Exacerbations of COPD: A Randomized, Controlled Trial Comparing Procalcitonin-Guidance With Standard TherapyChest, 2007
- Procalcitonin Guidance of Antibiotic Therapy in Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its PrecursorsJournal of Clinical Endocrinology & Metabolism, 2004
- Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trialThe Lancet, 2004
- Diagnostic Value of Procalcitonin, Interleukin-6, and Interleukin-8 in Critically Ill Patients Admitted with Suspected SepsisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Calcitonin precursors are reliable markers of sepsis in a medical intensive care unitCritical Care Medicine, 2000
- High serum procalcitonin concentrations in patients with sepsis and infectionThe Lancet, 1993